CD44是非酒精性脂肪性肝炎的关键驱动因子
研究在MCDD喂养的小鼠模型及肥胖患者中评估CD44对非酒精性脂肪性肝炎(NASH)的作用。CD44缺失或中和可减轻小鼠肝脏炎症、损伤和纤维化;肥胖患者肝CD44在NASH中上调并与NAFLD活动评分、气球样变、ALT及CCL2、CD68表达相关,血清可溶性CD44随严重脂肪变和NASH升高。结论提示CD44是肝脏炎症的标志和关键驱动因子,靶向CD44可部分纠正NASH。
要点
- CD44缺失小鼠在MCDD喂养下肝脏炎症、损伤和纤维化较野生型明显减轻。
- 中和CD44抗体可减少小鼠巨噬细胞浸润和CCL2表达,部分纠正肝脏炎症与损伤。
- 肥胖患者肝CD44在NASH中上调,且与NAS、气球样变、ALT、CCL2和CD68表达相关。
核心结论
- 人体和实验数据提示CD44是肝脏炎症的标志和关键驱动因子,靶向CD44可部分纠正NASH。
研究设计与样本
- 在CD44-/-小鼠和注射αCD44抗体的野生型小鼠中,以蛋氨酸-胆碱缺乏饮食(MCDD)诱导脂肪性肝炎模型评估CD44作用。
- 在肥胖患者中评估肝脏CD44(n=30,其中5例NASH患者在减重手术后行第二次肝活检)和血清可溶性CD44(n=64)。
主要发现
- 与野生型小鼠相比,CD44-/-小鼠在MCDD喂养下肝脏炎症(包括炎症灶数量、巨噬细胞和中性粒细胞浸润及CCL2/CCR2水平)、肝损伤和纤维化明显减轻。
- CD44缺失增强M2极化,并明显降低巨噬细胞对脂多糖(LPS)、肝细胞损伤相关分子模式(DAMPs)和饱和脂肪酸的活化。
- 在脂肪性肝炎小鼠中中和CD44可明显减少巨噬细胞浸润和趋化因子配体(CCL)2表达,并部分纠正肝脏炎症和损伤。
- 肥胖患者中,NASH患者肝脏CD44明显上调(p=0.0008),并与NAFLD活动评分(NAS)(p=0.001)、气球样变(p=0.003)、丙氨酸转氨酶(p=0.005)、肝脏CCL2(p<0.001)和巨噬细胞标志物CD68(p<0.001)表达相关。
- NASH纠正与肝脏CD44+细胞明显减少相关;血清可溶性CD44随严重脂肪变(p=0.0005)和NASH(p=0.007)升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Cluster of differentiation (CD)44 regulates adipose tissue inflammation in obesity and hepatic leukocyte recruitment in a lithogenic context. However, its role in hepatic inflammation in a mouse model of steatohepatitis and its relevance in humans have not yet been investigated. We aimed to evaluated the contribution of CD44 to non-alcoholic steatohepatitis (NASH) development and liver injury in mouse models and in patients at various stages of non-alcoholic fatty liver disease (NAFLD) progression. METHODS: The role of CD44 was evaluated in CD44-/- mice and after injections of an αCD44 antibody in wild-type mice challenged with a methionine- and choline-deficient diet (MCDD). In obese patients, hepatic CD44 (n=30 and 5 NASH patients with a second liver biopsy after bariatric surgery) and serum sCD44 (n=64) were evaluated. RESULTS: Liver inflammation (including inflammatory foci number, macrophage and neutrophil infiltration and CCL2/CCR2 levels), liver injury and fibrosis strongly decreased in CD44-/- mice compared to wild-type mice on MCDD. CD44 deficiency enhanced the M2 polarization and strongly decreased the activation of macrophages by lipopolysaccharide (LPS), hepatocyte damage-associated molecular patterns (DAMPs) and saturated fatty acids. Neutralization of CD44 in mice with steatohepatitis strongly decreased the macrophage infiltration and chemokine ligand (CCL)2 expression with a partial correction of liver inflammation and injury. In obese patients, hepatic CD44 was strongly upregulated in NASH patients (p=0.0008) and correlated with NAFLD activity score (NAS) (p=0.001), ballooning (p=0.003), alanine transaminase (p=0.005) and hepatic CCL2 (p<0.001) and macrophage marker CD68 (p<0.001) expression. Correction of NASH was associated with a strong decrease in liver CD44+ cells. Finally, the soluble form of CD44 increased with severe steatosis (p=0.0005) and NASH (p=0.007). CONCLUSION: Human and experimental data suggest that CD44 is a marker and key player of hepatic inflammation and its targeting partially corrects NASH. LAY SUMMARY: Human and experimental data suggest that CD44, a cellular protein mainly expressed in immune cells, is a marker and key player of non-alcoholic steatohepatitis (NASH). Indeed, CD44 enhances the non-alcoholic fatty liver (NAFL) (hepatic steatosis) to NASH progression by regulating hepatic macrophage polarization (pro-inflammatory phenotype) and infiltration (macrophage motility and the MCP1/CCL2/CCR2 system). Targeting CD44 partially corrects NASH, making it a potential therapeutic strategy.
引用
- Patouraux S, Rousseau D, Bonnafous S, et al. CD44 is a key player in non-alcoholic steatohepatitis. J Hepatol. 2017. PMID: 28323124. doi:10.1016/j.jhep.2017.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。